Skip to content
DataLookout
Menu

STANDNCT04522739

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

  1. Notable Results posted: Nov 20, 2026
  • Notable: the plan changed

Endpoints

Primary

Count of Adverse Events
Timeframe: Month 12
Number of Participants Not Completing The Study
Timeframe: Month 12

Secondary (5)

Change From Baseline in Trail Making Test Part A Score
Change From Baseline in Trail Making Test Part B Score
Change in From Baseline in Rey Auditory and Verbal Learning (RAVLT) Test Delayed Recall Score
Change From Baseline in Number Span Forward Test Score
Change From Baseline in Number Span Backward Test Score

Arms and interventions

SpironolactoneExperimental

Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for 12 months.

PlaceboPlacebo comparator

Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.

Drugs: Spironolactone, Placebo

Sites

1 site in 1 country

  • Emory Clinic at Executive ParkAtlanta, Georgia, United States